Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 750 of 770 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/23/24
End: 03/03/25
Due: 03/03/26
Phase: N/A
Priority: Normal
Start: 02/24/21
End: 04/19/21
Due: 04/19/22
Phase: N/A
Priority: Normal
Start: 09/14/18
End: 03/19/24
Due: 03/19/25
Phase: N/A
Priority: Normal
Start: 03/31/25
End: 12/01/28
Due: 12/01/29
Phase: N/A
Priority: Normal
Start: 09/30/15
End: 09/10/20
Due: 09/10/21
Phase: N/A
Priority: Normal
Start: 10/31/07
End: 09/30/29
Due: 09/30/30
Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer
Phase: N/A
Priority: Normal
Start: 09/30/05
End: 05/31/08
Due: 05/31/09
Phase: N/A
Priority: Normal
Start: 11/07/23
End: 09/30/24
Due: 09/30/25
Phase: N/A
Priority: Normal
Start: 03/01/21
End: 03/01/26
Due: 03/01/27
Phase: N/A
Priority: Normal
Start: 09/01/20
End: 12/31/21
Due: 12/31/22
Phase: N/A
Priority: Normal
Start: 01/31/16
End: 08/31/16
Due: 08/31/17
Phase: N/A
Priority: Normal
Start: 10/01/24
End: 10/08/24
Due: 10/08/25
Phase: N/A
Priority: Normal
Start: 11/01/18
End: 11/08/19
Due: 11/08/20
Phase: N/A
Priority: Normal
Start: 10/31/15
End: 08/31/18
Due: 08/31/19
Phase: N/A
Priority: Normal
Start: 06/30/07
End: 03/31/11
Due: 03/31/12
Phase: N/A
Priority: Normal
Start: 09/04/18
End: 11/01/23
Due: 11/01/24
Phase: N/A
Priority: Normal
Start: 08/25/15
End: 05/18/20
Due: 05/18/21
Phase: N/A
Priority: Normal
Start: 06/10/21
End: 07/24/24
Due: 07/24/25
Phase: N/A
Priority: Normal
Start: 01/31/15
End: 11/30/17
Due: 11/30/18
Phase: N/A
Priority: Normal
Start: 03/01/25
End: 04/01/26
Due: 04/01/27
Phase: N/A
Priority: Normal
Start: 10/31/14
End: 06/30/15
Due: 06/30/16
Phase: N/A
Priority: Normal
Start: 04/01/25
End: 12/01/26
Due: 12/01/27
Phase: N/A
Priority: Normal
Start: 08/22/18
End: 06/30/25
Due: 06/30/26
Phase: N/A
Priority: Normal
Start: 02/07/20
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 10/31/10
End: 05/31/17
Due: 05/31/18